An interventional study of Transcutaneous auricular neurostimulation in Abdominal Pain (AP) and Disorders of Gut-brain Interaction, sponsored by Nationwide Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Nationwide Children's Hospital · Not applicable, Interventional, and Treatment
Among 158 studies in Abdominal Pain with a site in United States — 23 open to participants now, 24 under way, 1 of them phase 3. Abdominal Pain · United States.
Among the 158 studies in Abdominal Pain with a site in United States, this one is the 92nd largest by planned enrollment of the 133 interventional ones that give a count, is one of 10 that started in 2025, is one of 74 with no phase, reaches primary completion later than 3 of the 23 other live ones, and was the 156th registered.
387 studies on the registry are indexed under Abdominal Pain; 58 are open to participants now.
This study's planned enrollment of 30 is below the median of 70 across 290 interventional studies indexed under Abdominal Pain.
Browse Abdominal Pain studies →23 of the 158 studies in Abdominal Pain with a site in United States are open now, in 1 country. Each count lists the studies.
Of the 33 Abdominal Pain studies recruiting now, 13 (39%) set no upper age limit and 17 (52%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 12 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →158 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 10 started in 2025.
Median enrollment 61 across the 133 interventional studies, 94 across the 24 observational. Of the 119 that completed or were terminated, 38 (32%) have results posted.
40 of 158 have an industry lead sponsor. The 10 most frequent:
Nationwide Children's Hospital is the lead sponsor of 233 studies on the registry; 43 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 9 (53%) have results posted.
Nationwide Children's Hospital has 1 study filed under Abdominal Pain — fewer than ten, so there is no comparison to draw.
11 of the studies in Abdominal Pain with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07927907Peach PerfectA Clinical Trial to Evaluate the Effects of a Supplement on Gut Health | 2026-11-01 |
| NCT07174609Johns Hopkins UniversityScrambler Therapy in Chronic Pancreatitis | 2026-12-01 |
| NCT07649720AnX Robotica Corp.NaviCam Patency Capsule to Verify Gastrointestinal Patency | 2026-12-15 |
| NCT06647615Mayo ClinicA Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease | 2026-12-31 |
| NCT07117032Case Comprehensive Cancer CenterSimulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy (SBRT) in Participants With Cancer-Related Celiac Pain | 2027-02 |
Among the 158 studies in Abdominal Pain with a site in United States, from their registry updates:
This single-site, open-label pilot study will evaluate transcutaneous auricular neurostimulation using the Sparrow Link device as a treatment for adolescents aged 12 to 18 years with abdominal pain related to disorders of gut-brain interaction. Up to 30 participants will be enrolled, with a goal of 20 completing the study. Participants will use the device for at least one hour daily for 4 weeks and complete questionnaires through week 8. The study will assess adherence, retention, safety, and preliminary changes in abdominal pain, bowel symptoms, quality of life, and anxiety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All participants receive active transcutaneous auricular neurostimulation using the Sparrow Link device for at least one hour daily for 4 weeks, with follow-up assessments through week 8.
Device: Transcutaneous auricular neurostimulation
Participants will use the wearable Sparrow Link device for at least one hour daily for 4 weeks. Self-adhesive electrodes placed on and around the ear deliver noninvasive electrical stimulation. Region 1 uses 30 Hz with a 500-microsecond pulse width, and Region 2 uses 100 Hz with a 250-microsecond pulse width. The duty cycle is 5 minutes on and 10 seconds off. Amplitude ranges from 0 to 5.0 mA and is adjusted to a comfortable level.
Also known as: Sparrow Link
Treatment Adherence Rate
Description: Percentage of the 28 prescribed intervention days with recorded Sparrow Link device use, calculated from device logs.
Time frame: During the 4-week intervention period.
Study completion rate
Percentage of enrolled participants who complete the 8-week study.
Time frame: From enrollment through week 8.
Change in Pain Frequency, Severity, and Duration
Pain Frequency-Severity-Duration Scale measures pain frequency from 0-7 days per week, usual and worst pain from 0-10, and pain duration. Higher pain scores indicate worse symptoms.
Time frame: Baseline through week 8
Change in Pediatric Quality of Life
Change in Pediatric Quality of Life Inventory score; higher scores indicate better quality of life.
Time frame: Baseline through week 8.
Change in Anxiety
Change in the State-Trait Anxiety Inventory for Children score; higher scores indicate greater anxiety.
Time frame: Baseline through week 8.
Change in Bristol Stool Form Scale
Average stool form over the previous week, rated from Type 1 to Type 7.
Time frame: Baseline through week 8.
Plan to share: No — Individual participant data will not be shared. Aggregate study results will be published. Any external data sharing would require prior Nationwide Children's Hospital approval and appropriate agreements.
Started Oct 2025 (actual). Primary completion is estimated for Oct 2026, 12 months after the start.
Of 85 non-industry interventional studies with no phase under Abdominal Pain, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's planned 12 months is below that.
Counting every sponsor, half of 101 studies reached it within 13 months; a quarter within 5 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nationwide Children's Hospital →